Advertisement
Product › Details
GPEx® technology
Next higher product group | cell line/system (recombinant protein production) | |
Status | 2018-05-14 production/use existent | |
Organisation | Catalent Pharma Solutions Inc. | |
Group | Catalent (Group) | |
Valerius Biopharma AG. (5/14/18). "Press Release: Catalent Biologics and Valerius Biopharma to Collaborate on Manufacture of Specialty Biosimilars". Somerset, NJ & Basel.
Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, and Valerius Biopharma AG, a Swiss biopharmaceutical company dedicated to providing interchangeable treatment options for high-priced orphan and nonorphan biologics, today announced that they are to collaborate on the development and manufacture of Valerius’ biosimilar products.
Under the agreement, Catalent Biologics will provide cell line development and support cGMP manufacturing activities from Phase I through to commercial stages at its state-of-the-art biologics manufacturing facility in Madison, Wisconsin.
The project will utilize Catalent’s proprietary GPEx® technology, which creates high-performance, highly stable production cell lines in a wide variety of mammalian host cells. To date, over 460 different mAb and mAb fusions, and over 50 different recombinant proteins have been produced using the GPEx system achieving large scale fed-batch production titers of over 7 g/L. The advantages of applying GPEx technology span from early feasibility studies, to clinical manufacturing, to commercial scale production.
Valerius Biopharma AG is a biopharmaceutical company founded to develop biosimilar products as alternatives to high-priced biologics, for indications where there is a substantial medical need. The company has built a research and development hub of scientists and experts with decades of experience in the development of biopharmaceutical and biosimilar compounds, as well as profound clinical and regulatory expertise. The company´s current product pipeline comprises four biosimilar products in different development stages.
“Our business mission is to make the treatment of severe, life-threatening and rare diseases more affordable for patients worldwide by developing biosimilars that meet the highest regulatory standards,” commented Andreas Herrmann, CEO of Valerius. He added, “We selected Catalent as our development and manufacturing partner because of their technical knowledge and expertise in the cGMP manufacture of biosimilars, and proven track record in bringing innovative treatments to market.”
Mike Riley, Vice President and General Manager of Drug Substance and Bioanalytical Services, Catalent Biologics, added, “We are pleased to partner with Valerius on their biologic-based therapeutics for many important indications. We look forward to supporting them in their goal of producing affordable biosimilars that will provide more equal access to medicinal products.”
Opened in April 2013 and recently expanded, Catalent Biologics’ Madison site provides development, manufacturing and analytical services for new biological entities and biosimilars. The facility was designed for flexible cGMP production from 10 liter up to 4,000 liter scale, and nonGMP production up to 250 liter scale and makes extensive use of single-use technologies and unidirectional flow to maximize safety and efficiency. Manufacturing is supported by integrated analytical, process and formulation development capabilities and separate microbiology and quality control functions.
-ends-
About Valerius
Valerius Biopharma AG is a Swiss biopharmaceutical company that has been founded to provide interchangeable treatment options for high-priced biologics, by developing specialty biosimilars for therapeutic indications with high medical need. The current product pipeline consists of two orphan and two non-orphan biosimilar drugs being developed according to highest regulatory standards to enable global access.
Valerius is committed to make the treatment of severe, life-threatening, and rare diseases more affordable for all patients worldwide. For further information, please visit www.valeriusbio.com.
About Catalent
Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With over 80 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs approximately 11,000 people, including over 1,400 scientists, at more than 30 facilities across five continents, and in fiscal 2017 generated over $2 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit www.catalent.com
More products. Better treatments. Reliably supplied.™
Media Contacts:
Chris Halling
+44 (0)7580 041073
chris.halling@catalent.com
Richard Kerns
+44 (0) 161 728 5880
richard@nepr.eu
Andreas Herrmann
+41 (0) 61 2053 910
andreas.herrmann@valeriusbio.com
Record changed: 2023-07-10 |
Advertisement
More documents for cell line/system (recombinant protein production)
- [1] ProBioGen AG. (3/13/24). "Press Release: ProBioGen Partners with Mapp Biopharmaceutical, Inc. for Groundbreaking Development of Afucosylated Antibody against Marburg Virus Disease Using GlymaxX Technology". Berlin....
- [2] ProBioGen AG. (1/10/23). "Press Release: ProBioGen Collaborates with Boehringer Ingelheim on DirectedLuck Transposase Technology". Berlin....
- [3] Glycotope GmbH. (2/1/22). "Press Release: Glycotope to Spin-out Its Service Business to the Newly Formed FyoniBio GmbH". Berlin....
- [4] Valneva S.E.. (11/10/21). "Press Release: Valneva Announces European Commission Approval of Advance Purchase Agreement for up to 60 Million Doses of Inactivated COVID-19 Vaccine VLA2001". Saint-Herblain....
- [5] Glycotope GmbH. (9/21/20). "Press Release: DCprime and Glycotope Sign Licensing Agreement to Advance Program Combining Cancer Vaccination and Therapeutic Antibody Platforms". Leiden & Berlin....
- [6] Intravacc B.V.. (9/8/20). "Press Release: Intravacc Receives US NIH/NIAID Contract to Develop Enterovirus D68 Vaccine". Bilthoven....
- [7] Rentschler Biopharma SE. (5/19/20). "Press Release: Rentschler Biopharma Licenses Horizon Discovery's CHOSource Platform to Complement Cell Line Development Offering for Difficult-to-Express Proteins". Laupheim, Milford, MA & Cambridge....
- [8] ProBioGen AG. (2/25/20). "Press Release: ImmunOs Therapeutics Selects ProBioGen for Development and Large-Scale Manufacturing Services". Berlin & Schlieren....
- [9] ProBioGen AG. (11/12/19). "Press Release: DirectedLuck, a Transposase for Efficient Gene Delivery and High-Titer Cell Line Development". Berlin....
- [10] Cevec Pharmaceuticals GmbH. (4/16/19). "Press Release: Cevec Closes Major Financing Round to Further Expand and Commercialize Its Viral Vector Manufacturing Platform". Cologne....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top